US OptionsDetailed Quotes

AKBA241220C2000

Watchlist

0.10
-0.05-33.33%

15min DelayClose Nov 29 13:00 ET

0.15High0.10Low

Akebia Therapeutics Stock Discussion

小竜

Nov 26 11:49

$Akebia Therapeutics (AKBA.US)$ Cup

小竜

Nov 15 10:44

$Akebia Therapeutics (AKBA.US)$ Its coming back 🥳🥳🥳

101674396

Nov 7 07:00

$Akebia Therapeutics (AKBA.US)$ .. sell past!!!

101674396

Nov 1 09:13

$Akebia Therapeutics (AKBA.US)$ .. good move!!

101674396

Oct 23 08:38

$Akebia Therapeutics (AKBA.US)$ .. may be chance to drop now!!!

Trytosaveabit

Oct 22 07:05

News

$Akebia Therapeutics (AKBA.US)$ Reuters
3 mins ago
Akebia Therapeutics Signs Commercial Supply Contract With Leading Dialysis Organization to Enable Access to Vafseo® (Vadadustat) for Patients on Dialysis! Expected to be available in USA in January 2025

101674396

Oct 17 04:52

$Akebia Therapeutics (AKBA.US)$ .. will turn to green!!

Trytosaveabit

Oct 10 07:07

Update

$Akebia Therapeutics (AKBA.US)$ Akebia Therapeutics Announces The CMS Has Determined That Vafseo Meets The Criteria For The Transitional Drug Add-On Payment Adjustment In The Anemia Management End-Stage Renal Disease Prospective Payment System Functional Category, Beginning On January 1, 2025.
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assig...

Stock_Drift

Oct 7 07:30

$Akebia Therapeutics (AKBA.US)$

Trytosaveabit

Oct 7 07:03

News

$Akebia Therapeutics (AKBA.US)$ Reuters· 1 min ago
Akebia Therapeutics Inc - Contract Enables Prescription of Vafseo for Dialysis Patients From Jan 2025

No comment yet